Penumbra Inc (PEN) stock
PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3074% above fair value
$320.62−0.29 (-0.09%)
Close on Nov 16, 2026Market cap $12.64BP/E 80.8Yield –
Penumbra EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Penumbra's EPS for the twelve months ending Sep 30, 2026 was $3.97, down 4.1% year over year. For fiscal 2025 it was $4.52, up 1155.6% from the year before. Over ten years it grew 49.7% a year on average. The highest annual figure on record is $4.52 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.52 | +1155.6% |
| FY2024 | Dec 31, 2024 | $0.36 | -84.5% |
| FY2023 | Dec 31, 2023 | $2.32 | – |
| FY2022 | Dec 31, 2022 | -$0.05 | -135.7% |
| FY2021 | Dec 31, 2021 | $0.14 | – |
| FY2020 | Dec 31, 2020 | -$0.44 | -132.8% |
| FY2019 | Dec 31, 2019 | $1.34 | +644.4% |
| FY2018 | Dec 31, 2018 | $0.18 | +38.5% |
| FY2017 | Dec 31, 2017 | $0.13 | -70.5% |
| FY2016 | Dec 31, 2016 | $0.44 | +450.0% |
| FY2015 | Dec 31, 2015 | $0.08 | – |
| FY2014 | Dec 31, 2014 | -$0.18 | -228.6% |
| FY2013 | Dec 31, 2013 | $0.14 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.07 | -8.5% |
| Q2 FY2026 | Jun 30, 2026 | $0.88 | -23.5% |
| Q1 FY2026 | Mar 31, 2026 | $0.82 | -18.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.20 | +46.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.17 | +56.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.15 | – |
| Q1 FY2025 | Mar 31, 2025 | $1.00 | +257.1% |
| Q4 FY2024 | Dec 31, 2024 | $0.82 | -40.6% |
| Q3 FY2024 | Sep 30, 2024 | $0.75 | +226.1% |
| Q2 FY2024 | Jun 30, 2024 | -$1.55 | -422.9% |
| Q1 FY2024 | Mar 31, 2024 | $0.28 | +27.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.38 | +1280.0% |
| Q3 FY2023 | Sep 30, 2023 | $0.23 | – |
| Q2 FY2023 | Jun 30, 2023 | $0.48 | – |
| Q1 FY2023 | Mar 31, 2023 | $0.22 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.10 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.06 | -125.0% |
| Q2 FY2022 | Jun 30, 2022 | -$0.10 | -140.0% |
| Q1 FY2022 | Mar 31, 2022 | $0.00 | -100.0% |
| Q4 FY2021 | Dec 31, 2021 | -$0.66 | -760.0% |
| Q3 FY2021 | Sep 30, 2021 | $0.24 | – |
| Q2 FY2021 | Jun 30, 2021 | $0.25 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.32 | +700.0% |
| Q4 FY2020 | Dec 31, 2020 | $0.10 | -63.0% |
| Q3 FY2020 | Sep 30, 2020 | -$0.24 | -175.0% |
| Q2 FY2020 | Jun 30, 2020 | -$0.34 | -173.9% |
| Q1 FY2020 | Mar 31, 2020 | $0.04 | -86.7% |
| Q4 FY2019 | Dec 31, 2019 | $0.27 | +50.0% |
| Q3 FY2019 | Sep 30, 2019 | $0.32 | – |
| Q2 FY2019 | Jun 30, 2019 | $0.46 | +24.3% |
| Q1 FY2019 | Mar 31, 2019 | $0.30 | +100.0% |
| Q4 FY2018 | Dec 31, 2018 | $0.18 | -28.0% |
| Q3 FY2018 | Sep 30, 2018 | -$0.55 | -5600.0% |
| Q2 FY2018 | Jun 30, 2018 | $0.37 | – |
| Q1 FY2018 | Mar 31, 2018 | $0.15 | – |
| Q4 FY2017 | Dec 31, 2017 | $0.25 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.01 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.05 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.10 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.08 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?